Article
Alanta Health Appoints Latham to Explore Options After Nordic Bond Deal Fails to Materialize
German oncology care provider Alanta Health has lined up Latham & Watkins to advise on a refinancing of its roughly €300 million of debts, sources said.
The appointment came after sponsor IK partners began work on a Nordic bond to refinance the debt late last year but did not ultimately launch a deal, as reported.
Bridgepoint Credit, then EQT Credit, provided €331 million of loans to support IK’s recapitalization of the business in 2019, according to a statement.
At the end of the first quarter of 2024, the loan agreement was amended and €30 million was repaid ahead of schedule, according to Alanta’s most recent publicly available accounts, from 2023.
The current talks remain at a very early stage, sources noted.
In 2020, the company became the subject of a police investigation, as reported by Bloomberg, into how its subsidiary ZytoService wins business from the doctors prescribing its drugs.
On June 2, 2025, Hamburg’s public prosecutor filed charges against two pharmacists and four individuals at companies primarily involved in the production of cytostatic drugs with the Hamburg regional court on suspicion of bribery and organized billing fraud, according to an emailed statement.
Alanta Health on June 2, confirmed that charges had been brought against individuals at the company and rejected the allegations that its managers circumvented the legal ban on cooperation between pharmaceutical service providers and contract physicians. It maintains that its patient care model, which uses medical care centers, or MVZ, is legally compliant and the quality of care is not in question.
A spokesperson for the public prosecutor told Octus that no decision has yet been made.
Alanta Health produces and sells drugs for parenteral infusions, primarily for the treatment of cancer. It employs 1,000 people across Germany, according to its website.
IK, Alanta Health and Latham did not respond to requests for comment.
This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.